The quarter showcased Amrutanjan's ability to sustain topline momentum, with net sales reaching an all-time quarterly high of ₹149.77 crores, marking the seventh consecutive quarter of revenue expansion. However, profitability metrics revealed underlying pressures, with the PAT margin contracting sharply to 10.81% from 13.79% in the previous quarter, primarily driven by a normalisation from the exceptionally strong December quarter. The stock has underperformed the broader market significantly, declining 20.54% over the past year against the Sensex's 3.74% fall, reflecting investor concerns over margin sustainability and competitive intensity in the consumer healthcare segment.
Financial Performance: Topline Strength, Bottom-Line Volatility
Amrutanjan's Q4 FY26 results present a tale of robust revenue growth tempered by margin fluctuations. Net sales of ₹149.77 crores represented sequential growth of 6.19% from Q3 FY26's ₹141.04 crores and year-on-year expansion of 10.60% from ₹135.41 crores in Mar'25. This marked the highest quarterly revenue in the company's recent history, driven by strong demand for its core pain relief balms and expanding product portfolio.
| Quarter | Net Sales (₹ Cr) | QoQ Growth | YoY Growth | Operating Margin | PAT Margin | Net Profit (₹ Cr) |
|---|---|---|---|---|---|---|
| Mar'26 | 149.77 | +6.19% | +10.60% | 17.06% | 10.81% | 16.19 |
| Dec'25 | 141.04 | +19.83% | +14.90% | 17.85% | 13.79% | 19.45 |
| Sep'25 | 117.70 | +25.15% | +7.08% | 14.04% | 11.86% | 13.96 |
| Jun'25 | 94.05 | -30.54% | — | 8.98% | 8.84% | 8.31 |
| Mar'25 | 135.41 | +10.31% | — | 13.07% | 11.21% | 15.18 |
| Dec'24 | 122.75 | +11.67% | — | 19.01% | 15.68% | 19.25 |
| Sep'24 | 109.92 | — | — | 12.37% | 10.74% | 11.80 |
Operating profit before depreciation, interest, and tax (excluding other income) stood at ₹25.55 crores in Q4 FY26, the highest quarterly PBDIT in recent quarters, though the corresponding margin of 17.06% contracted by 79 basis points sequentially from 17.85% in Q3 FY26. Year-on-year, however, the operating margin expanded by 399 basis points from 13.07%, indicating improved operational efficiency compared to the prior year period. The sequential margin compression appears to be a normalisation from the exceptionally strong December quarter, which typically benefits from seasonal demand patterns.
Net profit of ₹16.19 crores in Q4 FY26 reflected a PAT margin of 10.81%, down sharply from 13.79% in Q3 FY26 and marginally lower than 11.21% in Mar'25. The decline was partly attributable to a lower tax rate benefit in the previous quarter—Q3 FY26 saw a tax rate of 26.21% compared to 22.93% in Q4 FY26. Employee costs remained relatively stable at ₹15.65 crores, whilst other income contributed ₹4.73 crores, providing consistent non-operating support to profitability.
Capital Efficiency: Exceptional Returns Despite Growth Headwinds
Amrutanjan's balance sheet and capital efficiency metrics remain a standout feature, positioning the company amongst the more profitable small-cap pharmaceutical players. The company's average return on equity (ROE) of 18.42% over recent years demonstrates strong capital efficiency, with the latest ROE at 16.90%—a healthy level indicating effective utilisation of shareholder funds to generate profits. This high ROE is particularly impressive given the company's virtually debt-free capital structure, with average net debt to equity at -0.18, effectively making it a net cash company.
Capital Efficiency Highlights
Amrutanjan's average return on capital employed (ROCE) stands at an impressive 33.76%, with the latest ROCE at 21.24%. Higher ROCE values indicate superior capital productivity, and Amrutanjan's figure significantly exceeds the cost of capital, demonstrating the company's ability to generate strong returns on its invested capital. The average EBIT to interest coverage ratio of 53.83x reflects negligible debt obligations, whilst the debt to EBITDA ratio is characterised as "Net Debt is too low," underscoring the company's conservative financial management.
Shareholder funds totalled ₹108.74 crores as of Mar'16 (latest available annual data), comprising share capital of ₹2.92 crores and reserves of ₹105.82 crores. The company maintained zero long-term debt as of Mar'16, with current liabilities of ₹27.98 crores primarily consisting of trade payables of ₹9.28 crores. Fixed assets stood at ₹28.81 crores, whilst current assets of ₹100.49 crores and investments of ₹8.99 crores provided ample liquidity. The company's cash position of ₹42.42 crores as of Mar'16 reflected strong cash generation capabilities.
Concern: Whilst capital efficiency remains strong, the company's 5-year EBIT growth has been negative at -1.91%, indicating that whilst returns on invested capital are high, the absolute quantum of operating profit has contracted over the medium term. This suggests challenges in scaling the business or facing competitive pressures that have limited earnings expansion despite revenue growth of 10.37% over the same period.
Margin Dynamics: Seasonal Volatility and Cost Pressures
The pharmaceutical and consumer healthcare sector is characterised by seasonal demand patterns, and Amrutanjan's quarterly margin progression illustrates this dynamic clearly. The December quarter (Q3 FY26) typically represents a peak season for pain relief products, with colder weather driving higher consumption. This seasonality was evident in the 19.01% operating margin achieved in Dec'24 and 17.85% in Dec'25, compared to the more normalised 17.06% in Mar'26.
Gross profit margin in Q4 FY26 stood at 15.10%, a significant contraction from 19.85% in Q3 FY26 and 16.60% in Mar'25. This compression suggests either increased raw material costs, higher promotional expenses, or adverse product mix shifts. The PAT margin of 10.81% in Q4 FY26 remained below the company's historical averages, with the December quarters consistently delivering superior profitability—15.68% in Dec'24 and 13.79% in Dec'25.
Employee costs as a percentage of sales have remained relatively stable, ranging between 10.5% to 13.2% across recent quarters, indicating disciplined workforce management. However, the gap between operating margin (17.06%) and PAT margin (10.81%) of 625 basis points in Q4 FY26 highlights the impact of depreciation (₹1.61 crores), minimal interest (₹0.05 crores), and taxation (₹4.82 crores) on net profitability.
Industry Leadership: How Amrutanjan Compares to Peers
Within the pharmaceuticals and biotechnology sector, Amrutanjan occupies a distinctive position as a focused consumer healthcare player with a strong heritage brand. Compared to its peer group, the company demonstrates superior profitability metrics whilst trading at moderate valuation multiples.
| Company | P/E Ratio (TTM) | P/BV Ratio | ROE (%) | Dividend Yield (%) | Debt to Equity |
|---|---|---|---|---|---|
| Amrutanjan Health Care | 27.14 | 4.59 | 18.42 | 0.85 | -0.18 |
| Indoco Remedies | NA (Loss Making) | 2.24 | 7.83 | 0.09 | 1.13 |
| Solara Active | NA (Loss Making) | 1.51 | 2.54 | — | 0.51 |
| Kwality Pharma | 31.39 | 6.18 | 16.81 | — | 0.26 |
| Windlas Biotech | 26.22 | 3.28 | 11.97 | 0.69 | -0.43 |
| NGL Fine Chem | 41.36 | 4.84 | 16.28 | 0.07 | 0.11 |
Amrutanjan's ROE of 18.42% stands out as the highest amongst its peer group, significantly exceeding the peer average of approximately 11%. This superior capital efficiency reflects the company's ability to generate strong returns despite its asset-light business model. The company's P/E ratio of 27.14x appears moderate compared to NGL Fine Chem's 41.36x and slightly higher than Windlas Biotech's 26.22x, suggesting reasonable valuation relative to earnings power.
The price-to-book value (P/BV) ratio of 4.59x for Amrutanjan is higher than most peers except Kwality Pharma (6.18x), which can be justified by the company's superior ROE. The dividend yield of 0.85% exceeds most competitors, with only Windlas Biotech offering comparable shareholder returns at 0.69%. Notably, Amrutanjan's net cash position (debt to equity of -0.18) provides financial flexibility that several leveraged peers lack, particularly Indoco Remedies with debt to equity of 1.13.
Valuation Analysis: Attractive Entry Point After 30% Correction
Amrutanjan's shares have experienced significant volatility over the past year, declining 20.54% compared to the Sensex's 3.74% fall, creating a potentially attractive entry opportunity for long-term investors. The stock currently trades at ₹548.80, approximately 30.53% below its 52-week high of ₹789.95 and 12.00% above its 52-week low of ₹490.00.
At a P/E ratio of 27.14x, the stock trades below the industry average P/E of 35x, suggesting a valuation discount despite superior profitability metrics. The price-to-book value of 4.59x appears reasonable given the company's ROE of 16.90%, implying a price-to-earnings-to-growth (PEG) ratio of 1.58x. The EV/EBITDA multiple of 22.23x and EV/EBIT of 24.52x reflect moderate valuations for a profitable, debt-free consumer healthcare company with established brand equity.
The valuation grade has fluctuated between "Attractive" and "Fair" over recent months, with the current assessment being "Attractive" as of the latest update. This suggests that at current levels, the stock offers reasonable value relative to its earnings power and growth prospects. The dividend yield of 0.85%, whilst modest, is backed by a sustainable payout ratio of 26.16%, leaving ample room for reinvestment and future dividend growth.
Shareholding: Stable Promoter Base, Marginal Institutional Shifts
The shareholding pattern of Amrutanjan reflects a stable ownership structure with consistent promoter holding and moderate institutional participation. Promoter holding has remained unchanged at 46.52% across the last five quarters, indicating strong promoter confidence and alignment with minority shareholders. The absence of any pledged shares (0.0%) further reinforces the financial stability and commitment of the promoter group.
| Shareholder Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 | QoQ Change |
|---|---|---|---|---|---|
| Promoter Holding | 46.52% | 46.52% | 46.52% | 46.52% | 0.00% |
| FII Holding | 2.17% | 2.27% | 2.38% | 2.41% | -0.10% |
| Mutual Fund Holding | 7.02% | 7.55% | 7.55% | 7.55% | -0.53% |
| Insurance Holdings | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other DII Holdings | 5.64% | 5.45% | 5.35% | 6.67% | +0.19% |
| Non-Institutional | 38.65% | 38.21% | 38.20% | 36.86% | +0.44% |
Foreign institutional investor (FII) holding has witnessed a gradual decline from 2.41% in Jun'25 to 2.17% in Mar'26, with a sequential reduction of 0.10% in the latest quarter. This modest selling by FIIs may reflect profit-booking or portfolio rebalancing rather than fundamental concerns. Mutual fund holding decreased more noticeably from 7.55% to 7.02% in Mar'26, a reduction of 0.53% quarter-on-quarter, suggesting some institutional caution.
Interestingly, other domestic institutional investor (DII) holdings increased by 0.19% sequentially to 5.64%, partially offsetting the mutual fund and FII exits. Non-institutional holdings rose by 0.44% to 38.65%, indicating retail investor accumulation at lower price levels. The total institutional holding stands at 14.84%, comprising 28 FIIs and 4 mutual funds, providing a moderate institutional anchor to the stock.
Stock Performance: Significant Underperformance Across Timeframes
Amrutanjan's stock has delivered disappointing returns across multiple timeframes, consistently underperforming both the broader Sensex and its pharmaceutical sector peers. The shares declined 1.75% on May 08, 2026, closing at ₹548.80, and have fallen 3.80% over the past week compared to a 0.54% gain in the Sensex, resulting in negative alpha of -4.34%.
| Period | Stock Return | Sensex Return | Alpha | Sector Return |
|---|---|---|---|---|
| 1 Week | -3.80% | +0.54% | -4.34% | — |
| 1 Month | +3.15% | -0.30% | +3.45% | — |
| 3 Month | -13.15% | -7.48% | -5.67% | — |
| 6 Month | -22.47% | -7.08% | -15.39% | — |
| YTD | -17.86% | -9.26% | -8.60% | — |
| 1 Year | -20.54% | -3.74% | -16.80% | +12.90% |
| 2 Years | -28.92% | +5.26% | -34.18% | — |
| 3 Years | -7.17% | +25.20% | -32.37% | — |
The most concerning aspect is the stock's underperformance versus its pharmaceutical sector, which delivered +12.90% returns over the past year whilst Amrutanjan declined 20.54%—a staggering underperformance of -33.44%. This suggests company-specific challenges beyond broader sector trends. Over longer periods, the underperformance persists: the stock has fallen 28.92% over two years against the Sensex's 5.26% gain, and declined 7.17% over three years versus the Sensex's 25.20% advance.
The stock's beta of 1.35 indicates higher volatility than the market, with a volatility measure of 30.18% compared to the Sensex's 13.49%. The risk-adjusted return of -0.68 over one year, compared to the Sensex's -0.28, places Amrutanjan in the "Medium Risk Low Return" category—an unfavourable combination for investors. The stock currently trades below all major moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), reinforcing the bearish technical trend.
Investment Thesis: Quality Company, Challenged Momentum
The investment case for Amrutanjan rests on a foundation of strong fundamental quality tempered by near-term momentum challenges. The company's overall quality grade of "Good" reflects solid long-term financial performance characterised by zero debt, strong return ratios, and disciplined capital allocation. However, the current proprietary score of 55/100 places it in "HOLD" territory, down from a "BUY" rating in late 2025.
The financial trend assessment for Q4 FY26 is "Positive," driven by record quarterly sales of ₹149.77 crores and highest quarterly PBDIT of ₹25.55 crores. This positive momentum in absolute financial metrics contrasts with the "Mildly Bearish" technical trend, which turned negative on May 06, 2026. The valuation assessment of "Attractive" at current levels suggests the stock offers reasonable entry points for long-term investors, particularly given the 30% correction from recent highs.
Key Strengths & Risk Factors
KEY STRENGTHS
- Exceptional Capital Efficiency: Average ROE of 18.42% and ROCE of 33.76% demonstrate superior returns on invested capital, significantly above peer averages
- Zero Debt Balance Sheet: Net cash position with debt to equity of -0.18 provides financial flexibility and eliminates refinancing risks
- Record Revenue Performance: Q4 FY26 net sales of ₹149.77 crores represent all-time quarterly high, with consistent topline expansion over seven quarters
- Strong Interest Coverage: EBIT to interest ratio of 53.83x reflects negligible debt servicing burden and robust operating profitability
- Attractive Valuation: P/E of 27x trades below industry average of 35x despite superior profitability metrics, offering value opportunity
- Established Brand Equity: Heritage brand with strong consumer recall in pain relief segment provides competitive moat
- No Promoter Pledging: Zero pledged shares indicate strong promoter financial health and alignment with shareholders
KEY CONCERNS
- Margin Volatility: PAT margin contracted to 10.81% from 13.79% sequentially, indicating pressure on profitability despite revenue growth
- Negative EBIT Growth: 5-year EBIT CAGR of -1.91% suggests challenges in scaling operating profits despite 10.37% sales growth
- Persistent Underperformance: Stock down 20.54% over one year vs Sensex decline of 3.74%, and 33.44% underperformance vs pharmaceutical sector
- Bearish Technical Trend: Trading below all key moving averages with mildly bearish indicators across timeframes
- Institutional Selling: FII and mutual fund holdings declined by 0.10% and 0.53% respectively in Q4 FY26
- High Volatility: Beta of 1.35 and volatility of 30.18% expose investors to above-market price fluctuations
- Limited Institutional Coverage: Only 4 mutual funds and 28 FIIs hold the stock, limiting liquidity and research coverage
Outlook: What to Watch
POSITIVE CATALYSTS
- Margin Recovery: Improvement in PAT margins above 12% would signal successful cost management and pricing power
- Sustained Revenue Momentum: Maintaining double-digit topline growth for next 2-3 quarters would validate market share gains
- New Product Launches: Expansion beyond core pain relief portfolio could drive incremental revenue streams
- Technical Reversal: Reclaiming 200-day moving average (₹650.60) would improve sentiment and attract momentum buyers
- Institutional Accumulation: Reversal in FII/MF selling trend would provide demand support
RED FLAGS
- Further Margin Compression: PAT margins falling below 10% would raise concerns about business model sustainability
- Revenue Growth Deceleration: Quarterly sales growth slipping to mid-single digits would signal competitive intensity
- Promoter Stake Reduction: Any decline in 46.52% promoter holding would be viewed negatively by the market
- Break Below 52-Week Low: Decisive breach of ₹490 support could trigger further technical selling
- Continued Institutional Exits: Accelerated FII/MF selling would pressure valuations and liquidity
The Verdict: Quality Franchise, Patience Required
Score: 55/100
For Fresh Investors: Wait for margin stabilisation and technical trend reversal before initiating positions. Current levels offer reasonable value for patient investors with 18-24 month horizon, but near-term momentum remains challenged. Consider accumulating in tranches below ₹540 with fair value estimate of ₹620-650.
For Existing Holders: Continue to hold. The stock's quality fundamentals (18.42% ROE, zero debt, strong brand) remain intact despite near-term margin pressures. The 30% correction has created attractive risk-reward for long-term wealth creation. Avoid panic selling at current depressed levels.
Fair Value Estimate: ₹635 (15.70% upside from current price of ₹548.80)
Rationale: Amrutanjan represents a high-quality, debt-free consumer healthcare franchise trading at attractive valuations after significant correction. Whilst near-term margin pressures and negative technical momentum warrant caution, the company's superior capital efficiency, established brand equity, and record revenue performance provide a solid foundation for patient investors. The key risk lies in the company's inability to translate revenue growth into proportionate earnings expansion, as evidenced by negative 5-year EBIT growth. However, at 27x P/E versus 35x industry average and with ROE of 18.42%, the current valuation offers reasonable margin of safety for long-term holders.
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. The views expressed herein are those of the Investment Research Desk and do not constitute a recommendation to buy, sell, or hold any security.
